Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is in a strong financial position with a solid revenue growth rate of 8-12% driven by new product launches and international expansion. However, one risk is the delay in clinical trials or new product approvals, which could impact the company's revenue growth. Another risk is worse than expected stent graft sales, which could also hinder revenue growth. Despite these risks, the company has a strong pipeline and product portfolio that positions it for potential upside in the future, supporting a positive outlook.

Bears say

Artivion is a medical device company with a negative outlook, as their recent quarterly results indicated a top-line beat but lowered revenue and EBITDA guidance for the full year. Their bear case scenario predicts a share price of $18, based on a 2027 sales estimate of 2.0x EV/sales. While the company has potential for long-term growth, with opportunities for new product launches and expansion into international markets, there are concerns about delays and potential issues with suppliers. Additionally, the company's use of free cash flow for future earn-outs and debt repayment may limit potential returns for investors.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.